Hepatitis C Therapeutic Development and Pipeline Review H1 2015 Research Report

DALLAS, March 18, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Hepatitis C - Pipeline Review, H1 2015" therapeutic market research report of 639 pages with latest updates, data and information to its online business intelligence library.

The report "Hepatitis C - Pipeline Review, H1 2015" provides an overview of the Hepatitis C's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Hepatitis C is a liver disease caused by the hepatitis C virus. The virus can cause both acute and chronic hepatitis infection, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. There are many types of hepatitis C virus. The most common in the U.S. is type 1. No type is more serious than any other, but they respond differently to treatment. Hepatitis C is an increasing public health concern in the United States and throughout the world. Symptoms of Hepatitis C include jaundice, stomach pain, loss of appetite, nausea and fatigue. 3, 50,000 to 5, 00,000 people die each year from hepatitis C-related liver diseases. Complete report is available @http://www.rnrmarketresearch.com/hepatitis-c-pipeline-review-h1-2015-market-report.html  .

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Companies discussed in this report include 3-V Biosciences, Inc., AbbVie Inc., Achillion Pharmaceuticals, Inc., Adaptimmune Limited, AiCuris GmbH & Co. KG, AIMM Therapeutics B.V., Akshaya Bio Inc., Alnylam Pharmaceuticals, Inc., Altor BioScience Corporation, Amarna Therapeutics B.V., American Gene Technologies International Inc., Anacor Pharmaceuticals, Inc., ARA Healthcare Pvt. Ltd., Arrowhead Research Corporation, Ascendis Pharma A/S, Astex Pharmaceuticals, Inc., Biogenomics Limited, BioLineRx, Ltd., Bionor Pharma ASA, Biotest AG, Biotron Limited, Bolder Biotechnology, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Chiasma, Inc., Chugai Pharmaceutical Co., Ltd., Cocrystal Pharma, Inc., Conatus Pharmaceuticals Inc., Crucell N.V., Debiopharm International S.A., DEKK-TEC, Inc., Delpor, Inc., Digna Biotech, S.L., DiscoveryBiomed, Inc., Enanta Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Genecode AS, GeneCure LLC, Gilead Sciences, Inc., GlaxoSmithKline plc, HanAll Biopharma Co., Ltd., Hanmi Pharmaceuticals, Co. Ltd., HEC Pharm Co., Ltd., Hepacyl Therapeutics, SL, Hependo Sp. z o. o. (Ltd), Hetero Drugs Limited, Humabs BioMed SA, ImmunoBiology Ltd., Immunocore Limited, Immunomedics, Inc., Immunotech Laboratories, Inc., Inbiopro Solutions Pvt. Ltd., Inovio Pharmaceuticals, Inc., Integrated BioTherapeutics, Inc., iTherX, Inc., Johnson & Johnson, Kineta, Inc., Koronis Pharma, Inc., LG Life Sciences, Ltd., Ligand Pharmaceuticals, Inc., Meda AB, Medivir AB, Merck & Co., Inc., Microbio Co., Ltd., Microbiotix, Inc., Myelo Therapeutics GmbH, Novartis AG, Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Peregrine Pharmaceuticals, Inc., Pfenex Inc., Pfizer Inc., PharmaEssentia Corporation, Polaris Pharmaceuticals, Inc., Presidio Pharmaceuticals, Inc., Profectus BioSciences, Inc., Quintessence Biosciences, Inc., Regulus Therapeutics Inc., RFS Pharma, LLC, Rodos BioTarget GmbH, Romark Laboratories, L.C., Seek , SelectX Pharmaceuticals, Inc., SKAU Vaccines ApS, SomaGenics Inc., Sorrento Therapeutics, Inc., Spring Bank Pharmaceuticals, Inc., StemCells, Inc., Summit Corporation plc, Tacere Therapeutics, Inc., TaiGen Biotechnology Co., Ltd., Therapure Biopharma Inc., Theravectys S.A., Transgene SA, United Therapeutics Corporation, Vakzine Projekt Management GmbH, Vaxeal Holding SA, VBI Vaccines, Vertex Pharmaceuticals Incorporated, ViroLogik GmbH, WaterStone Pharmaceuticals, Inc., WhanIn Pharmaceutical Co., Ltd., Xenetic Biosciences plc. Order a Purchase copy of this report @http://www.rnrmarketresearch.com/contacts/purchase?rname=310120  . (This is a premium report priced at US$2000 for a single user License.)

Drugs profile discussed in this report include (asunaprevir + daclatasvir), (daclatasvir + asunaprevir + beclabuvir), (danoprevir + ritonavir), (grazoprevir + elbasvir), (ledipasvir + sofosbuvir), (ombitasvir + paritaprevir + ritonavir) + dasabuvir, (paritaprevir + ritonavir + ombitasvir), (ribavirin + hydroxychloroquine), (sofosbuvir + GS-5816), ABT-493, ABT-493 + ABT-530, ABT-530, ACH-3080, ACH-3102, ACH-3107, ACH-3422, ACP-007, AG-1104, AIC-649, AL-335, AL-516, alisporivir, Antiviral TCR-Ck, Antiviral TCR-Ig, ARABS-3, ARABS-4, ARABS-5, asunaprevir, AT-26893, AV-4025, AV-4203, AVL-181, AVL-192, AVR-560, bavituximab, BBT-012, beclabuvir, BIT-225, BIT-314, BL-8030, BZF-961, CDI-244, Cell Therapy for HCV/Diabetes, CIGB-230, CPI-43132, Creaferon, daclatasvir dihydrochloride, DAG-181, danoprevir, dasabuvir, DCBF-1, deldeprevir, Dendritic Cell Therapy for Hepatitis C, Dimethylpyridine, DL-2014, DLP-201, Drug for Hepatitis C Infections, Drug for Infectious Diseases, Drugs for HCV Infection, Drugs to Antagonize Type I Interferon Receptor for Viral Infections, Drugs to Inhibit NS5B for Hepatitis C, E-2216, EDP-239, EDP-239 + alisporivir, EDP-546, elbasvir, emricasan, Fluoropyridone-19, furaprevir, Gene Therapy for Hepatitis B and Hepatitis C, Gene Therapy for Hepatitis C, grazoprevir, GS-563253, GS-5816, GS-9256, GS-9620, GS-9669, GS-9857, etc.

Explore more reports of Hepatitis Drugs Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/hepatitis-drugs .

Related reports on Hepatitis Drugs Market:

Hepatitis D - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Hepatitis D.  Companies discussed in this report include Alnylam Pharmaceuticals, Inc., BioDiem Ltd, Eiger BioPharmaceuticals, Inc., Globeimmune, Inc., Hepatera LLC, REPLICor Inc., SomaGenics Inc.

Hepatitis B - Pipeline Review, H2 2014

This report provides comprehensive information on the therapeutic development for Hepatitis B. Companies discussed in this report include Abivax, AiCuris GmbH & Co. KG, Akshaya Bio Inc., Alnylam Pharmaceuticals, Inc., AlphaMab Co., Ltd, AltraVax Inc., Amarna Therapeutics B.V., Arrowhead Research Corporation, Assembly Biosciences, Inc., Beijing Minhai Biotechnology Co., Ltd, Benitec Biopharma Limited, Big DNA Ltd., BioDiem Ltd, Biological E. Limited, BioStar Pharmaceuticals, Inc., Bolder Biotechnology, Inc., Bukwang Pharm.Co., Ltd., CEL-SCI Corporation, Celltrion, Inc.

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@rnrmarketresearch.com